Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | WNT3 | P56703 | 1/20 | 0.39 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476304 | 1.00 | KMT2A (0.41) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL476303 | 1.00 | KMT2A (0.41) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL1604617 | 0.91 | MMP2 (0.38) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL1604618 | 0.91 | MMP2 (0.38) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL18018362 | 0.91 | MMP2 (0.38) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL713924 | 0.91 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL1372911 | 0.91 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL12105456 | 0.91 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL30289778 | 0.91 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL6743320 | 0.88 | CHRM2 (0.38) | CHRM2CHRM1CHRM3WNT3SFRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079866-A | Preparation method of Nenoxacin side chain isomer impurity | — | 2026-05-26 | — | — | CN | claimed |
| CN-105294700-B | A kind of preparation method of 2- oxo -3,8- diazabicylo [3.2.1] octane -8- carboxylic acid tert-butyl ester | 上海合全药业股份有限公司 | 2019-01-08 | — | — | CN | claimed |
| CN-106336371-A | Synthetic method of Boc-L-Pyroglutamic acid methyl ester | 成都百事兴科技实业有限公司 | 2017-01-18 | — | — | CN | claimed |
| EP-1229041-A1 | A process for the preparation of 3-Glutamido bile ester derivatives using N-tBoc methyl pyroglutamate | Bracco Imaging S.p.A. (IT) | 2002-08-07 | — | — | EP | claimed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122079866-A | Preparation method of Nenoxacin side chain isomer impurity | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079866-A | Preparation method of Nenoxacin side chain isomer impurity | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109669-A1 | SYNTHESIS OF (2S,5R)-5-(2-CHLOROPHENYL)-1-(2'-METHOXY-[1,1'-BIPHENYL]-4- CARBONYL)PYRROLIDINE-2-CARBOXYLIC ACID | EPICS THERAPEUTICS (BE) | 2026-04-23 | — | — | US | disclosed |
| US-12545677-B2 | Compounds useful as factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-10 | — | — | US | disclosed |
| US-20260035393-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528769-B2 | Synthesis of (2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid | EPICS THERAPEUTICS (BE) | 2026-01-20 | — | — | US | disclosed |
| EP-1529776-A2 | Amino acid derivatives and sweetening agent | Ajinomoto Co., Inc. (JP) | 2005-05-11 | — | — | EP | disclosed |
| EP-1523483-A2 | AMINO-BICYCLIC PYRAZINONES AND PYRIDINONES AS COAGULATION SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20050038030-A1 | Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-17 | — | — | US | disclosed |
| US-20040138185-A1 | Process for the preparation of 3-glutamido bile ester derivatives using n-prtotected methyl proglutamate | BROCCHETTA MARINO | 2004-07-15 | — | — | US | disclosed |
| WO-2004002405-A2 | AMINO-BICYCLIC PYRAZINONES AND PYRIDINONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-08 | — | — | WO | disclosed |
| EP-1358201-A1 | A PROCESS FOR THE PREPARATION OF 3-GLUTAMIDO BILE ESTER DERIVATIVES USING N-PROTECTED METHYL PYROGLUTAMATE | BRACCO IMAGING S.p.A. (IT) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002068449-A1 | A PROCESS FOR THE PREPARATION OF 3-GLUTAMIDO BILE ESTER DERIVATIVES USING N-PRTOTECTED METHYL PROGLUTAMATE | BRACCO IMAGING S.P.A. (IT) | 2002-09-06 | — | — | WO | disclosed |
| EP-1229041-A1 | A process for the preparation of 3-Glutamido bile ester derivatives using N-tBoc methyl pyroglutamate | Bracco Imaging S.p.A. (IT) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | KMT2A 4265/4885CHRM2 4756/4885CHRM1 4566/4885 |
| US-20040138185-A1 | Process for the preparation of 3-glutamido bile ester derivatives using n-prtotected methyl proglutamate | GCG, GPBAR1, OTC | KMT2A 3026/4885CHRM2 2685/4885CHRM1 1181/4885 |
| US-20260109669-A1 | SYNTHESIS OF (2S,5R)-5-(2-CHLOROPHENYL)-1-(2'-METHOXY-[1,1'-BIPHENYL]-4- CARBONYL)PYRROLIDINE-2-CARBOXYLIC ACID | TPMT, CLIC1, CYP2S1 | KMT2A 1675/4885CHRM2 1068/4885CHRM1 871/4885 |
| US-12545677-B2 | Compounds useful as factor XIa inhibitors | F2, F11, F10 | KMT2A 3070/4885CHRM2 4441/4885CHRM1 3928/4885 |
| US-20050038030-A1 | Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors | TFPI, F5, F2 | KMT2A 2629/4885CHRM2 4543/4885CHRM1 4094/4885 |
| US-20260035393-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNI | KMT2A 1303/4885CHRM2 4473/4885CHRM1 4128/4885 |
| US-12528769-B2 | Synthesis of (2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid | ADH1C, ADH1A, IL6 | KMT2A 1575/4885CHRM2 498/4885CHRM1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.